Zobrazeno 1 - 10
of 115
pro vyhledávání: '"John C. Byrd"'
Autor:
James S. Blachly, Uma Borate, Eunice S. Wang, Bhavana Bhatnagar, Ross L. Levine, Ann-Kathrin Eisfeld, Amy Burd, John C. Byrd, Richard Stone, Brian J. Druker, Alice S. Mims, Krzysztof Mrόzek, Eytan M. Stein, Bayard L. Powell, Jonathan E. Kolitz, Clara D. Bloomfield, Shelley Orwick, Jessica Kohlschmidt, Dimitrios Papaioannou, Deedra Nicolet
Publikováno v:
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-15 (2021)
Journal of Hematology & Oncology
Journal of Hematology & Oncology
Background Older patients (≥ 60 years) with acute myeloid leukemia (AML) often have multiple, sequentially acquired, somatic mutations that drive leukemogenesis and are associated with poor outcome. Beat AML is a Leukemia and Lymphoma Society-spons
Autor:
Elizabeth M. Muhowski, Janani Ravikrishnan, Britten Gordon, Lianbo Yu, Shrilekha Misra, Brandi Walker, Sudharshan Eathiraj, Deepa Sampath, Kerry A. Rogers, John C. Byrd, Jennifer A. Woyach
Publikováno v:
Journal of hematologyoncology. 15(1)
Inhibitors of B cell receptor (BCR) signaling such as the Bruton’s tyrosine kinase (BTK) inhibitors are effective therapeutics for chronic lymphocytic leukemia (CLL). The first-in-class covalent BTK inhibitor, ibrutinib, produces durable responses
Autor:
Sunnia T. Chen, Leylah Azali, Lindsay Rosen, Qiuhong Zhao, Tracy Wiczer, Marilly Palettas, John Gambril, Onaopepo Kola-Kehinde, Patrick Ruz, Sujay Kalathoor, Kerry Rogers, Adam Kittai, Michael Grever, Farrukh Awan, John C. Byrd, Jennifer Woyach, Seema A. Bhat, Daniel Addison
Publikováno v:
Journal of Hematology & Oncology. 15
Background Post-market analyses revealed unanticipated links between first-generation Bruton’s tyrosine kinase inhibitor (BTKi) therapy, ibrutinib, and profound early hypertension. Yet, whether this is seen with novel selective second (next)-genera
Autor:
Anna Eames Seffernick, Krzysztof Mrózek, Deedra Nicolet, Richard M Stone, Ann-Kathrin Eisfeld, John C Byrd, Kellie J Archer
Publikováno v:
Briefings in bioinformatics. 23(6)
For many high-dimensional genomic and epigenomic datasets, the outcome of interest is ordinal. While these ordinal outcomes are often thought of as the observed cutpoints of some latent continuous variable, some ordinal outcomes are truly discrete an
Autor:
Marius Bill, Bayard L. Powell, John C. Byrd, Brian Giacopelli, Jessica Kohlschmidt, Jonathan E. Kolitz, Dimitrios Papaioannou, Christopher C. Oakes, Ramiro Garzon, Krzysztof Mrózek, Richard Stone, Andrew J. Carroll, Ann-Kathrin Eisfeld, Deedra Nicolet, Clara D. Bloomfield
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-4 (2021)
Recently, a novel knowledge bank (KB) approach to predict outcomes of individual patients with acute myeloid leukemia (AML) was developed using unbiased machine learning. To validate its prognostic value, we analyzed 1612 adults with de novo AML trea
Autor:
Rosa Lapalombella, Pu Zhang, Shaneice Mitchell, Amy Lehman, Bonnie K. Harrington, Deepa Sampath, Matthew Cannon, John C. Byrd, Larry Beaver
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-5 (2021)
KPT-9274 is a phase 1 first-in-class dual PAK4/NAMPT inhibitor for solid tumor and non-Hodgkin’s lymphoma. It demonstrates pre-clinical efficacy toward a broad spectrum of acute myeloid leukemia (AML) subtypes by inhibiting NAMPT-dependent NAD+ pro
Autor:
Kevin M. Huang, Erin Hertlein, Bill Larsen, Robert J. Weber, Daelynn R. Buelow, John C. Byrd, Josie A. Silvaroli, Sharyn D. Baker, Shelley Orwick, Eric D. Eisenmann, Sydney Fobare, Jae Yoon Jeon, Jack Stromatt
Publikováno v:
The FASEB Journal. 35
Autor:
Clara D. Bloomfield, Bayard L. Powell, Andrew J. Carroll, Shelley Orwick, Ann-Kathrin Eisfeld, Jessica Kohlschmidt, Bhavana Bhatnagar, Dimitrios Papaioannou, Richard Stone, Deedra Nicolet, Krzysztof Mrózek, John C. Byrd, Jonathan E. Kolitz, Christopher J. Walker, James S. Blachly
Publikováno v:
Leukemia. 34:358-368
Sole trisomies of chromosomes 4, 8, 11, 13 and 21 account for 89–95% of all sole trisomies in adult AML patients. We analyzed clinical and molecular characteristics of 138 de novo AML patients with sole +4, +8, +11, +13 or +21, and compared them wi
Autor:
Zachary A. Hing, Jennifer A. Woyach, Katie Williams, Kerry A. Rogers, Brian Giacopelli, Neil E. Kay, Jordan M. Baumhardt, Matthew K. Summers, Benjamin R. Stromberg, Sameer A. Parikh, Sharon Shacham, Janek S. Walker, Christopher C. Oakes, Rosa Lapalombella, Vincenzo Coppola, Thomas J. Kipps, Qingxiang Sun, Bonnie K. Harrington, Hatice Gulcin Ozer, Larry Beaver, Laura Z. Rassenti, Amy Lehman, Jordan N. Skinner, Yuh Min Chook, Casey Cempre, Lynne V. Abruzzo, John C. Byrd
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-21 (2021)
Journal of hematology & oncology, vol 14, iss 1
Journal of Hematology & Oncology, Vol 14, Iss 1, Pp 1-21 (2021)
Journal of hematology & oncology, vol 14, iss 1
BackgroundExportin 1 (XPO1/CRM1) is a key mediator of nuclear export with relevance to multiple cancers, including chronic lymphocytic leukemia (CLL). Whole exome sequencing has identified hot-spot somaticXPO1point mutations which we found to disrupt
Autor:
James S. Blachly, Shelley Orwick, Jordan N. Skinner, Steven Sher, Katie Williams, Matthew Cannon, Amy Lehman, Daniel Canfield, Lindsey T. Brinton, Pu Zhang, Bonnie K. Harrington, Rosa Lapalombella, Casey Cempre, John C. Byrd, Mukul Govande, Larry Beaver, Ronni Wasmuth
Publikováno v:
Journal of Hematology & Oncology
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Journal of Hematology & Oncology, Vol 13, Iss 1, Pp 1-10 (2020)
Acute myeloid leukemia (AML) is a heterogeneous and complex disease, and treatments for this disease have not been curative for the majority of patients. In younger patients, internal tandem duplication of FLT3 (FLT3-ITD) is a common mutation for whi